Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Barhate, Shashikant D.
- Form Fill Seal Technology:A Brief Review
Abstract Views :473 |
PDF Views:0
Authors
Affiliations
1 Shri. Sureshadada Jain Institutes of Pharmaceutical Education and Research, Jamner, Maharashtra, IN
1 Shri. Sureshadada Jain Institutes of Pharmaceutical Education and Research, Jamner, Maharashtra, IN
Source
Asian Journal of Pharmaceutical Research, Vol 7, No 4 (2017), Pagination: 244-246Abstract
Form fill seal (FFS) technology is an automated computer operated technology, to prepare sterile products. Mostly it is applicable for I.V. infusion bottles. In this process all steps such as formation of container, filling of container with content and sealing of container are performed sequentially, consistently and automatically in a closed sterile chamber of machine. This technology reduces the contamination rate below 0.1%. The reason behind FFS technology is to reduce the contamination during production in a closed sterile chamber of a machine. Thus there should be no personnel intervention to reduce the chances of contamination during the manufacturing of sterile products. Again it gives more production in very low operational cost with high assurance of sterility.Keywords
Sterile, Moulds, Parison, Class 100 Area, I.V. Bottles.
References
- http://www.pharmaguideline.com/2013/12/blow-fill-seal-bfs-and-form-fill-seal-ffs-in-sterile-production.html
- http://www.ppma.co.uk/form-fill-seal.htm
- http://www.reiser.com/pdf/RepakBrochure.pdf
- http://www.sacmi.com/System/00/02/17/21769/ed_itIT/FFS%20Form%20-%20Fill%20-%20Seal%20machine_2013_09_72dpi.pdf
- Citric Acid Cross Linked Cellulose Based Hydrogel for Drug Delivery
Abstract Views :472 |
PDF Views:0
Authors
Affiliations
1 Shri. Sureshadada Jain Institutes of Pharmaceutical Education and Reasearch, Jamner, Maharashtra, IN
1 Shri. Sureshadada Jain Institutes of Pharmaceutical Education and Reasearch, Jamner, Maharashtra, IN
Source
Asian Journal of Pharmaceutical Research, Vol 7, No 4 (2017), Pagination: 247-255Abstract
The main objective of this investigation was to formulate controlled release dosage form by using citric acid cross linked cellulose based hydrogel. Hydrogels were prepared by cross liking the polymer HPMC-K4M by using suitable cross linking agent, citric acid. Due to cross linking reaction hydrogel gave good swelling as well as controlled release property to metoprolol succinate hydrogels. In this study 32 full factorial design, which was augmented for 2 central points was used by using Design-Expert 8.0.7.1. It gave 11 runs. In this design the concentration of citric acid (X1) and reaction time (X2) were selected as independent variables, while as drug content, swelling index and t75 of % cumulative drug release were selected as dependent variables. From the results it can be concluded that the effect of citric acid concentration on drug content and t75 of % CDR was nonsignificant. But the effect of citric acid concentration on swelling index was much significant, means as citric acid concentration increased; there was decrease in swelling index of hydrogel. Again effect of reaction time on drug content as well as on t75 of % CDR was much significant, means as reaction time increased; there was increase in drug content as well as t75 of %CDR of hydrogel. But the effect of reaction time on swelling index was nonsignificant. On the basis of all responses obtained, drug content, swelling index and t75 of % CDR of run R1 are best. Drug content, swelling index and t75 of % CDR of this run are 99.5%, 276.64% and 207.6 min. respectively. So optimized formulation was run R1, which gave the best in vitro release up to 94.24% in 360 min (6hrs).IR and DSC study shows no evidence on interaction between drug, polymers and other excipient. The in vitro data were fitted to different kinetic models.Keywords
Swellable Hydrogel, Factorial Design, Cross Linking Agent, Metoprolol Succinate, HPMC.References
- Chein YW. Novel Drug Delivery Systems. New York: Marcel Dekker Inc. 1992; 139-196.
- Vyas SP, Khar RK. Controlled Drug Delivery Concepts and Advances. New Delhi: Vallabh Publication. 2010; 155-170.
- Jain NK. Progress in Controlled and Novel Drug Delivery Systems, New Delhi: CBS Publication. 2010; 341-360.
- Donald L. Handbook of Pharmaceutical Controlled Release Technology, New York: Marcel Dekker, Inc. 2008; 211-216.
- Hoare TR, Kohane DS. Hydrogels in Drug Delivery: Progress and challenges. Cambridge: Polymer. 2008; 4(1): 1993-2007.
- Donald L. Handbook of Pharmaceutical Controlled Release Technology, New York: Marcel Dekker, Inc. 2008; 217-224.
- Chein YW. Novel Drug Delivery Systems. New York: US Informa Healthcare, Inc. 2011; 91-93.
- Vyas SP, Khar RK. Controlled Drug Delivery Concepts and advances. New Delhi: Vallabh Publication. 2010; 171-195.
- Sannino A. Application of superabsorbent hydrogels for the optimization of water resources in agriculture. 3rd International Conference on Water Resources and Arid Environments, 1st Arab Water Forum. Saudi Arabia. 2008; 1-10.
- Mobocertinib Is an Oral Kinase Inhibitor Targeted Against EFGR and Used in the Treatment of Non-small Cell Lung Cancer: A Review
Abstract Views :61 |
PDF Views:0
Authors
Affiliations
1 Shree Sureshdada Jain Institute of Pharmaceutical Education and Research, Jamner, Maharashtra, IN
1 Shree Sureshdada Jain Institute of Pharmaceutical Education and Research, Jamner, Maharashtra, IN
Source
Asian Journal of Pharmaceutical Research, Vol 12, No 2 (2022), Pagination: 179 - 182Abstract
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used particularly in the action of non-small cell lung cancer (NSCLC) caused by exon 20 placing mutations in the EGFR gene, which are classically linked through a poorer prognosis (as compared to "classical" EGFR mutants causing NSCLC) and are linked with opposition to standard targeted EGFR inhibitors. Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on EGFR exon 20 insertion mutant variants at concentrations 1.5- to 10-fold lower than those required to inhibit wild-type EGFR.2 Mobocertinib, below the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated agreement by the FDA in September 2021 for the action of locally advanced or metastatic NSCLC in patients with EGFR exon 20 insertion mutations who have failed previous therapies.1
Keywords
Mobocertinib, non-small cell lung cancer, EGFR exon 20 insertion mutationsReferences
- www.drug bank.com
- FDA Approved Drug Products: Exkivity (mobocertinib) capsules for oral use
- Bethune G, Bethune D, Ridgway N, Xu Z: Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010; 2(1): 48-51.
- Vyse S, Huang PH: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019; 4: 5. doi: 10.1038/s41392-019-0038-9. eCollection 2019
- Zhang S, Jin S, Griffin C, Feng Z, Lin J, Baratta M, Brake R, Venkatakrishnan K, Gupta N: Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low- Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. Clin Pharmacol Drug Dev. 2021 Sep; 10(9): 1028-1043. doi: 10.1002/cpdd.951. Epub 2021 Jun 12.
- FDA grants accelerated approval to mobocertinib for metastatic non-sma". U.S. Food and Drug Administration (FDA). 16 September 2021. Retrieved 16 September 2021. This article incorporates text from this source, which is in the public domain.
- "What Is Non-Small Cell Lung Cancer?". www.cancer.org.
- "Non-small cell lung cancer treatment – National Cancer Institute". 1 January 1980. Retrieved 19 October 2008.
- Non-small cell lung cancer". University of Maryland Medical Center. Retrieved 4 December 2017.
- Liu X, Conner H, Kobayashi T, Kim H, Wen F, Abe S, et al. (August 2005). "Cigarette smoke extract induces DNA damage but not apoptosis in human bronchial epithelial cells". American Journal of Respiratory Cell and Molecular Biology. 33 (2): 121–9.